Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)

Site Reference ID/Investigator# 7689, Barcelona

Site Reference ID/Investigator# 8052, Genoa

Site Reference ID/Investigator# 7789, Milan

Site Reference ID/Investigator# 7698, Madrid

Site Reference ID/Investigator# 7693, Madrid

Site Reference ID/Investigator# 7691, Madrid

Site Reference ID/Investigator# 11461, Huntersville

Site Reference ID/Investigator# 8426, Charlotte

Site Reference ID/Investigator# 8429, Decatur

Site Reference ID/Investigator# 8395, Atlanta

Site Reference ID/Investigator# 8425, Orlando

Site Reference ID/Investigator# 8396, Vero Beach

Site Reference ID/Investigator# 8394, Atlantis

Site Reference ID/Investigator# 8402, Tampa

Site Reference ID/Investigator# 7960, Montpellier

Site Reference ID/Investigator# 8393, Ft. Pierce

Site Reference ID/Investigator# 7690, Seville

Site Reference ID/Investigator# 7695, Lyon

Site Reference ID/Investigator# 8063, Paris

Site Reference ID/Investigator# 7821, Paris

Site Reference ID/Investigator# 8403, Dallas

Site Reference ID/Investigator# 8433, Houston

Site Reference ID/Investigator# 8431, Phoenix

Site Reference ID/Investigator# 8432, Beverly Hills

Site Reference ID/Investigator# 8424, Boston

Site Reference ID/Investigator# 7963, Ottawa

Site Reference ID/Investigator# 7831, Toronto

Site Reference ID/Investigator# 7959, Toronto

Site Reference ID/Investigator# 8099, Montreal

Site Reference ID/Investigator# 8051, Perugia

Site Reference ID/Investigator# 8050, Rome

Site Reference ID/Investigator# 8221, Wroclaw

Site Reference ID/Investigator# 7713, Bayamón

Site Reference ID/Investigator# 7700, Ponce

Site Reference ID/Investigator# 11102, Barcelona

Site Reference ID/Investigator# 7697, Barcelona

Site Reference ID/Investigator# 7692, L'Hospitalet de Llobregat